Related Experiment Video
Updated: Mar 25, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes
Rose Anderson1, Jennifer Hayes1, Jeffrey W Stephens1,2
1a Department of Diabetes & Endocrinology , Morriston Hospital, ABM University Health Board , Swansea , UK.
Introduction:
Dipeptide peptidase-4 (DPP-4) inhibitors such as saxagliptin are established and efficacious oral therapies in the management of type 2 diabetes. These agents have the potential to confer significant benefits in glycemic control without the risk of weight gain and hypoglycemia, which may be associated with other medications used to treat type 2 diabetes.
Areas Covered:
This review examines the pharmacokinetics, efficacy and tolerability of saxagliptin for the management of type 2 diabetes.
Expert Opinion:
Saxagliptin is routinely used in the management of type 2 diabetes as monotherapy, and in combination with other oral agents and insulin. Robust clinical trials have shown consistent improvements in glycated hemoglobin, fasting and postprandial glucose levels, with few adverse effects. The agent is well tolerated with low rates of hypoglycemia in the absence of insulin or sulphonylurea therapy.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacodynamic Responses: Different Types
